Monoclonal Antibody Therapy for Cancer

Annual Review of Medicine

Volumn 54, Issue , 2003, Pages 343-369

  Von Mehren, Margaret ^a   Adams, Gregory P ^a   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Antibody dependent cellular cytotoxicity; Immunoconjugate; Immunotoxin; Radioimmunotherapy

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE DERIVATIVE; ANTIBODY CONJUGATE; APOLIZUMAB; B LYMPHOCYTE ANTIGEN; BEVACIZUMAB; CALCIUM CHELATING AGENT; CASPASE INHIBITOR; CD20 ANTIGEN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; EPRATUZUMAB; GEMCITABINE; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; IMMUNOTOXIN;

ACNE; ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CELL GROWTH; CELL SURFACE; CEREBROVASCULAR ACCIDENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONJUGATION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DYSPNEA; EFFECTOR CELL; EPIGLOTTITIS; FEVER; FLUSHING; HERPES SIMPLEX; HISTOPATHOLOGY; HUMAN; HYPOXEMIA; IMMUNE RESPONSE; LUNG ASPERGILLOSIS; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; META ANALYSIS; NONHODGKIN LYMPHOMA; PEMPHIGUS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN TARGETING; RASH; REVIEW; RIGOR; SEBORRHEIC DERMATITIS; SEPTICEMIA; SKIN TOXICITY; SOLID TUMOR; STATISTICAL MODEL; STEVENS JOHNSON SYNDROME; STRUCTURE ANALYSIS; TARGET CELL; THROMBOCYTOPENIA; THROMBOSIS; THRUSH; TOXIC EPIDERMAL NECROLYSIS; TUBERCULOSIS; TUMOR CELL DESTRUCTION; IMMUNOLOGY; NEOPLASM; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; NEOPLASMS; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 0013110937     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.54.101601.152442     Document Type: Review

References (135)

1. Sivolapenko GB, Douli V, Pectasides D, et al. 1995. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumor antibody. Lancet 346:1662-66
2. Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. 1999. Di-, tri-and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding. FEBS Lett. 453:164-68
3. Ward ES, Gussow D, Griffiths AD, et al. 1989. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544-46
4. Huston JS, Levinson D, Mudgett-Hunter M, et al. 1988. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in E coli. Proc. Natl. Acad. Sci. USA 85:5879-83
5. Marks JD, Hoogenboom HR, Bonnert TP, et al. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581-97
6. Begent RH, Verhaar MJ, Chester KA, et al. 1996. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 2:979-84
7. Adams GP, McCartney JE, Tai MS, et al. 1993. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 53:4026-34
8. Holliger P, Prospero T, Winter G. 1993. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90:6444-48
9. Hu SSL, Raubitschek A, Sherman M, et al. 1996. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56:3055-61
10. Jain RK. 1990. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. (Suppl.) 50:814s-19s
11. Jain RK, Baxter LT. 1988. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48:7022-32
12. Trauth B, Klas C, Peters A, et al. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-5
13. Waldman T. 1991. Monoclonal antibodies in diagnosis and therapy. Science 252:387-94
14. O'Connell M, Chen Z, Yang H, et al. 1989. Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors. Semin. Surg. Oncol. 5:441-47
15. Houghton A, Mintzer D, Cordon-Cardo C, et al. 1985. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA 82:124-46
16. Steplewski Z, Lubeck M, Koprowski H. 1983. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 221:865-67
17. Lindenmann J. 1973. Speculations on Ids and homobodies. Ann. Immunol. 124: 171-84
18. Jerne N. 1974. Towards a network theory of the immune system. Ann. Immunol. 125:373-89
19. Miller R, Maloney D, Warnke R, Levy R. 1982. Treatment of B-cell lymphoma with monocolonal anti-idiotype antibody. N. Engl. J. Med. 306:517-22
20. Khazaeli M, Conry R, LoBuglio A. 1994. Human immune responses to monoclonal antibodies. J. Immunother. 15:42-52
21. Peterson J, Couto J, Taylor M, Ceriani R. 1995. Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer. Cancer Res. 55:5847s-51s
22. Badger C, Anasetti C, Davis J, Bernstein I. 1987. Treatment of malignancy with unmodified antibody. Pathol. Immunopathol. Res. 6:419-34
23. Holland G, Zlotnik A. 1993. Interleukin-10 and cancer. Cancer Invest. 11:751-58
24. Norgaard P, Hougaard S, Poulsen H, Thomsen M. 1995. Transforming growth factorβ and cancer. Cancer Treat. Rev. 21:367-403
25. Lee J, Fenton BM, Koch CJ, et al. 1998. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res. 58:1478-85
26. Nadler L, Stashenko P, Hardy R, et al. 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 40:3147-54
27. Vuist W, Levy R, Maloney D. 1994. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 83:899-906
28. Swisher E, Shawler D, Collins H, et al. 1991. Expression of shared idiotypes in chronic lymphocytic leukemia and small lymphocytic lymphoma. Blood 77:1977-82
29. Bowen A, Zomas A, Emmett E, et al. 1997. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br. J. Haematol. 96:617-19
30. Lundin J, Osterborg A, Brittinger G, et al. 1998. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J. Clin. Oncol. 16:3257-63
31. Hale G, Zhang M, Bunjes D, et al. 1998. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 92:4581-90
32. Naparstek E, Delukina M, Or R, et al. 1999. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. Exp. Hematol. 27:1210-18
33. Novitzky N, Thomas V, Hale G, Waldmann H. 1999. Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect. Transplantation 67:620-26
34. Hale G, Waldmann H. 1998. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 91:3079-83
35. Maloney D, Grillo-López A, Bodkin D, et al. 1997. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15:3266-74
36. Maloney D, Grillo-López A, White C, 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-95
37. Shan D, Ledbetter J, Press O. 2000. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol. Immunother. 48:673-83
38. McLaughlin P, Grillo-López A, Link B, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16:2825-33
39. Berinstein N, Grillo-López A, White C, et al. 1998. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 9:995-1001
40. Coiffier B, Haioun C, Ketterer N, et al. 1998. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927-32
41. Heinzerling L, Dummer R, Kempf W, et al. 2000. Intralesional therapy with anti-CD 20 monoclonal antibody rituximab in primary cutaneous lymphoma. Arch. Dermatol. 136:374-78
42. Czuczman M, Grillo-López A, White C, et al. 1999. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 17:268-76
43. Demidem A, Lam T, Alas S, et al. 1997. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12:177-86
44. Gribben J, Freedman A, Woo S, et al. 1991. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275-80
45. Czuczman M. 2002. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin. Oncol. 20:36-40
46. Howard O, Gribben J, Neuberg D, et al. 2002. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol. 20:1288-94
47. Mangel J, Buckstein R, Imrie K, et al. 2002. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin. Oncol. 29:56-69
48. Piro L, White C, Grillo-López A, et al. 1999. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10:619-21
49. Keating M, O'Brien S. 2000. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin. Oncol. 27:86-90
50. 49a. Maloney DG, Smith B, Rose A. 2002. Rituximab: mechanisms of action and resistance. Semin. Oncol. 29(1 Suppl. 2):2-9
51. Davis T, Czerwinski D, Levy R. 1999. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin. Cancer Res. 5:611-15
52. Nabhan C, Rosen ST. 2002. Conceptual aspects of combining rituximab and campath-1H in the treatment of chronic lymphocytic leukemia. Semin. Oncol. 29: 75-80
53. Leonard J, Link B. 2002. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (Epratuzumab, an anti-CD22 monoclonal antibody) and HuIDI0 (Apolizumab). Semin. Oncol. 29:81-86
54. Byrd J, Waselenko J, Maneatis T, et al. 1999. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells : association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol. 17:791-95
55. Jensen M, Winkler U, Manze O, et al. 1998. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann. Hematol. 77:89-91
56. Grillo-López A, Hedrick E, Rashford M, Benyunes M. 2002. Rituximab: ongoing and future clinical development. Semin. Oncol. 29:102-12
57. Cobleigh M, Vogel C, Tripathy D, et al. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:2639-48
58. Baselga J, Tripathy D, Mendelsohn J, et al. 1996. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14:737-44
59. Petit A, Rak J, Hung M, et al. 1997. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151:1523-30
60. Slamon D, Leyland-Jones B, Shak S, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:783-92
61. Norton L, Slamon D, Leyland-Jones B. 1999. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin® (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 18:A127 (Abstr.)
62. Baselga J. 2001. Clinical trials of Herceptin® (trastuzumab). Eur. J. Cancer 37:S18-S24
63. Burstein HJ, Kuter I, Campos SM, et al. 2001. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 19:2722-30
64. her2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16:2659-71
65. Miller KD, Sisk J, Ansari R, et al. 2001. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology 15:S38-S40
66. Bookman M, Darcy K, Clarke-Pearson D, et al. 2002. Evaluation of monoclonal humanized anti-HER2 antibody (Trastuzumab, Herceptin) in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 20: In press
67. Modjtahedi H, Komurasaki T, Toyoda H, Dean C. 1998. Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF, and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours. Int. J. Cancer 75:310-16
68. Teramoto T, Onda M, Tokunaga A, Asano G. 1996. Inhibitory effect of an anti-epidermal growth factor receptor antibody on human gastric cancer. Cancer 77:1639-45
69. Sato J, Kawamoto T, Le A, et al. 1983. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1:511-29
70. Artega C, Corondo E, Osbore C. 1988. Blockade of the epidermal growth factor receptor inhibits transforming growth factor a-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol. Endocrinol. 2:1064-69
71. Hoffman T, Hafner D, Ballo H, et al. 1997. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 17:4419-25
72. Fan Z, Baselga J, Masui H, Mendelsohn J. 1993. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53:4637-42
73. Baselga J, Norton L, Masui H, et al. 1993. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. 85:1327-33
74. Ciardiello F, Bianco R, Damiano V, et al. 1999. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 5:909-16
75. Bonner J, Raisch K, Robert HT, et al. 2000. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol. 18 (Suppl.):47s-53s
76. Modjtahedi H, Eccles S, Sandle J, et al. 1994. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Res. 54:1695-701
77. Sunada H, Magun B, Mendelsohn J, MacLeod C. 1986. Monoclonal antibody against the EGF receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sci. USA 83:3825-28
78. Sunada H, Yu P, Peacock J, Mendelsohn J. 1990. Modulation of tyrosine serine and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by anti-receptor monoclonal antibody. J. Cell. Physiol. 142:284-92
79. Fan Z, Masui M, Altas I, Mendelsohn J. 1993. Blockade of the epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 53:4322-28
80. Prewett M, Rockwell R, Giorgio N, et al. 1996. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunother. Emphasis Tumor Immunol. 19:419-27
81. Zolfaghari A, Djakiew D. 1996. Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function. Prostate 28:232-38
82. Peng D, Fan Z, Lu Y, et al. 1996. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 56:3666-69
83. Wu X, Rubin M, Fan Z, et al. 1996. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12:1397-403
84. Baselga J, Pfister D, Cooper M, et al. 2000. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18:909-14
85. Herbst R, Langer C. 2002. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 29:27-36
86. Shin D, Donato N, Perez-Soler R, et al. 2001. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7:1204-13
87. Mendez M, Green L, Corvalan J, et al. 1997. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15:146-56
88. Yang X, Jia X, Corvalan J, et al. 1999. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59:1236-43
89. Haga Y, Sivinski C, Woo D, Tempero M. 1994. Dose related comparison of antibody-dependent cellular cytotoxicity with chimeric and native monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. Int. J. Pancreatol. 15:43-50
90. Meredith R, LoBuglio A, Plott W, et al. 1991. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1 17-1A monoclonal antibody. J. Nucl. Med. 32:1162-68
91. Takamuku K, Baba K, Aringa S, et al. 1996. Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: enhancement with interferon gamma. Cancer Immunol. Immunother. 43:220-25
92. Reali E, Guiliani A, Spisani S, et al. 1994. Interferon-gamma enhances monoclonal antibody 17-1A-dependent neutrophil cytotoxicity toward colorectal carcinoma cell line SW11-16. Clin. Immunol. Immunopathol. 71:105-12
93. Ragnhammar P, Masucci G, Frodin J, et al. 1992. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb-17-1A and granulocyte/macrophage colony stimulating factor. Cancer Immunol. Immunother. 35:158-64
94. Ragnhammar P, Magnusson I, Masucci G, Mellstedt H. 1993. The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GMCSF in the treatment of colorectal carcinoma (CRC). Med. Oncol. Tumor Pharmacother. 10:61-70
95. Masucci G, Ragnhammar P, Wersall P, Mellstedt H. 1990. Granulocyte-monocyte colony-stimulating factor augments the interleukin-2 induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A). Cancer Immunol. Immunother. 31:231-35
96. Wersall P, Masucci G, Mellstedt H. 1991. Interleukin-4 augments cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. 33:45-49
97. Reali E, Spisani S, Gacili R, et al. 1995. IL-8 enhances antibody dependent cellular cytotoxicity in human neutrophils. Immunol. Cell Biol. 73:234-38
98. Weiner L, Steplewski Z, Koprowski H, et al. 1986. Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma. Hybridoma 5:S65-77
99. Ragnhammar P, Fagerberg J, Frodin J, et al. 1993. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma -long-lasting, complete remissions can be induced. Int. J. Cancer 53:751-58
100. Frodin J, Faxas M, Hagstrom B, et al. 1991. Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome - an important antitumoral effector function? Hybridoma 10:421-31
101. Hanzawa Y, Tsujisaki M, Tokuchi S, et al. 1992. Detection of xenogeneic anti-idiotypic antibodies specific to murine monoclonal antibody 17-1A in patients with gastrointestinal cancer. Tumour Biol. 13:226-36
102. Fagerberg J, Frodin J, Wigzell H, Mellstedt H. 1993. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab-1 reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy? Cancer Immunol. Immunother. 37:264-70
103. Ragnhammar P, Fagerberg J, Frodin J-E, et al. 1995. Granulocyte/ macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies to therapeutic monoclonal antibodies. Cancer Immunol. Immunother. 40:367-75
104. Shetye J, Ragnhammar P, Liljefors M, et al. 1998. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 4:1921-29
105. Fagerberg J, Frodin J, Ragnhammar P, et al. 1994. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Cancer Immunol. Immunother. 38:149-59
106. Sears H, Herlyn D, Steplewski Z, Koprowski H. 1985. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res. 45:5910-13
107. Weiner L, Harvey E, Padavic-Shaller K, et al. 1993. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1a therapy in pancreatic carcinoma. J. Immunother. 13:110-16
108. Reithmuller G, Schneider-Gadicke E, Schlimok G, et al. 1994. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343:1177-83
109. Reithmuller G, Holz E, Schlimok G, et al. 1998. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. 16:1788-94
110. Dencausse Y, Hartung G, Sturm J, et al. 2001. Prospective randomized study of adjuvant therapy with edrecolomab (Panorex)® of stage II colon cancer -interim analysis. Proc. Am. Soc. Clin. On col. 21:A2198 (Abstr.)
111. Gordon M, Margolin K, Talpaz M, et al. 2001. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19:843-50
112. Sledge G, Miller K, Novotny W, et al. 2000. A phase II trial of single agent rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 20:A5C (Abstr.)
113. Notovny W, Holmgren E, Griffing S, et al. 2001. Identification of squamous cell histology and central cavitary tumors as possible risk factors for pulmonary hemorrhage (PH) in patients with advanced NSCLC receiving Bevacizumab (B). Proc. Am. Soc. Clin. Oncol. 21:A1318 (Abstr.)
114. DeVore R, Fehrenbacher L, Herbst R, et al. 2000. A randomized phase II trial comparing RhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Oncol. 20: A1896 (Abstr.)
115. Bergsland E, Hurwitz H, Fehrenbacher L, et al. 2000. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluoruracil/leucovorin (FU/LV) in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 20:A939 (Abstr.)
116. Witzig TE, White CA, Wiseman GA, et al. 1999. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 (+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17:3793-803
117. Williams LE, Liu A, Wu AM, et al. 1995. Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies. Med. Phys. 22:2025-27
118. Press OW, Eary JF, Appelbaum FR, et al. 1993. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329: 1219-24
119. 131I] anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329:459-65
120. Kaminski MS, Zasadny KR, Francis IR, et al. 1996. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14:1974-81
121. Caron PC, Scheinberg DA. 1993. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia. Leukemia Lymphoma 11(Suppl. 2):1-6
122. White CA, Weaver RL, Grillo-López AJ. 2001. Antibody-targeted immunotherapy for treatment of malignancy. Annu. Rev. Med. 52:125-45
123. Witzig TE, Gordon LI, Cabanillas F, et al. 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20:2453-63
124. 131I-Lym-1 antibody. Cancer Biother. Radiopharm. 13:239-54
125. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J. Clin. Oncol. 16:3246-56
126. Jurcic JG, Caron PC, Nikula TK, et al. 1995. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 55(23 Suppl): 5908s-10s
127. Jurcic JG, Divgi CR, McDevitt MR, et al. 1998. Potential for myeloablation with yttrium-90-HuM195 (anti-CD33): a phase I trial in advanced myeloid leukemias. Blood 92:613A (Abstr.)
128. Jurcic JG, McDevitt MR, Sgouros G, et al. 1999. Phase I trial of targeted alpha particle therapy for myeloid leukemias with bismuth-213-HuM195 (anti-CD33). Proc. Am. Soc. Clin. Oncol. 18:7A (Abstr.)
129. 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin. Cancer Res. 5(Suppl.):3254s-58s
130. 90Y-2IT-BAD-m170 for metastatic prostate cancer. Clin. Cancer Res. 7: 1561-68
131. Meredith RF, Alvarez RD, Partridge EE, et al. 2001. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother. Radiopharm. 16:305-15
132. DeNardo SJ, Kramer EL, O'Donnell RT, et al. 1997. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J. Nucl. Med. 38:1180-85
133. Paganelli G, Grana C, Chinol M, et al. 1999. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med. 26:348-57
134. Knox SJ, Goris ML, Tempero M, et al. 2000. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 6:406-14
135. Weiden PL, Breitz HB, Press O, et al. 2000. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer. Biother. Radiopharm. 15: 15-29